Bevacizumab in recurrent glioblastoma
Year: 2019
Type: article
Abstract: In May 2009, the U.S. Food and Drug Administration granted accelerated approval for the use of bevacizumab in patients with progressive glioblastoma (GBM), the most common malignant primary brain tumor in adults (1). Neovascularization is a morphologic hallmark of GBM, driven in part by vascular endothelial growth factor A (VEGF-A) which is targeted and neutralized by bevacizumab.
Source: Translational Cancer Research
DOI: 10.21037/26303
Authors: Nina Martinez, Jon Glass, Wenyin Shi
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W2907576978